Share：
Share this content in WeChat
X
[Chinese][PDF]32810
• Clinlcal Guidelines & Expert Consensus •
Chinese expert consensus on the evaluation of neurological immune-related adverse reactions in malignant tumors treated with immune checkpoint inhibitors by MRI
Molecular Imaging Group of Chinese Society of Radiology of Chinese Medical Association
MRI Group of Chinese Society of Radiology Chinese Medical Association
Neurology Group of Chinese Society of Radiology Chinese Medical Association
Editorial Board of Chinese Journal of Magnetic Resonance Imaging

Cite this article as: Molecular Imaging Group of Chinese Society of Radiology of Chinese Medical Association; MRI Group of Chinese Society of Radiology Chinese Medical Association; Neurology Group of Chinese Society of Radiology Chinese Medical Association, et al. Chinese expert consensus on the evaluation of neurological immune-related adverse reactions in malignant tumors treated with immune checkpoint inhibitors by MRI[J]. Chin J Magn Reson Imaging, 2024, 15(12): 1-9, 18. DOI:10.12015/issn.1674-8034.2024.12.001.


[Abstract] In recent years, cancer immunotherapy, especially immune checkpoint inhibitors (ICIs), has become an important breakthrough in tumor treatment, significantly improving patient prognosis. However, the occurrence of immune-related adverse events (irAEs), particularly those affecting the nervous system, is one of the main limitations of cancer immunotherapy, with an associated mortality rate exceeding 5%. MRI plays a key role in detecting and assessing neurological irAEs. However, there is currently a lack of standardized consensus in China regarding MRI examination and diagnosis of neurological irAEs caused by ICIs. To address this, the Molecular Imaging Group, Magnetic Resonance Group, and Neurology Group of the Radiology Branch of the Chinese Medical Association, along with the Editorial Board of Chinese Journal of Magnetic Resonance Imaging, are committed to formulating a consensus on MRI examination and diagnostic reporting for neurological irAEs caused by ICIs. After reviewing the literature, expert experience, and internal member discussions, this committee has reached a consensus aimed at providing more accurate empirical support for imaging and clinical physicians and promoting the application of MRI technology in the diagnosis of neurological irAEs.
[Keywords] magnetic resonance imaging；immune checkpoint inhibitors；neurological immune-related adverse reactions；clinical application；expert consensus

Molecular Imaging Group of Chinese Society of Radiology of Chinese Medical Association   MRI Group of Chinese Society of Radiology Chinese Medical Association   Neurology Group of Chinese Society of Radiology Chinese Medical Association   Editorial Board of Chinese Journal of Magnetic Resonance Imaging  

Corresponding author: SUN H Z (Department of Radiology, Shengjing Hospital Affiliated to China Medical University, Shenyang 110004, China), E-mail: sunhongzan@126.com JU S H (Department of Radiology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China), E-mail: jsh@seu.edu.cn

Conflicts of interest   None.

Received  2024-10-01
Accepted  2024-12-10
DOI: 10.12015/issn.1674-8034.2024.12.001
Cite this article as: Molecular Imaging Group of Chinese Society of Radiology of Chinese Medical Association; MRI Group of Chinese Society of Radiology Chinese Medical Association; Neurology Group of Chinese Society of Radiology Chinese Medical Association, et al. Chinese expert consensus on the evaluation of neurological immune-related adverse reactions in malignant tumors treated with immune checkpoint inhibitors by MRI[J]. Chin J Magn Reson Imaging, 2024, 15(12): 1-9, 18. DOI:10.12015/issn.1674-8034.2024.12.001.

[1]
BAXI S, YANG A N, GENNARELLI R L, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis[J/OL]. BMJ, 2018, 360: k793 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/29540345/. DOI: 10.1136/bmj.k793.
[2]
KHOJA L, DAY D, WEI-WU CHEN T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review[J]. Ann Oncol, 2017, 28(10): 2377-2385. DOI: 10.1093/annonc/mdx286.
[3]
Committee of Neoplastic Supportive-Care of China Anti-Cancer Association, Cancer Clinical Chemotherapy Committee of China Anti-Cancer Association. Chinese expert consensus on diagnosis and treatment of neurologic immune-related adverse events associated with immune checkpoint inhibitors (2022 edition)[J]. Chin J Oncol, 2022, 44(9): 935-941. DOI: 10.3760/cma.j.cn112152-20220213-00098.
[4]
WESLEY S F, HAGGIAGI A, THAKUR K T, et al. Neurological immunotoxicity from cancer treatment[J/OL]. Int J Mol Sci, 2021, 22(13): 6716 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/34201529/. DOI: 10.3390/ijms22136716.
[5]
BERZ A M, BOUGHDAD S, VIETTI-VIOLI N, et al. Imaging assessment of toxicity related to immune checkpoint inhibitors[J/OL]. Front Immunol, 2023, 14: 1133207 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/36911692/. DOI: 10.3389/fimmu.2023.1133207.
[6]
LAU D, CORRIE P G, GALLAGHER F A. MRI techniques for immunotherapy monitoring[J/OL]. J Immunother Cancer, 2022, 10(9): e004708 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/36122963/. DOI: 10.1136/jitc-2022-004708.
[7]
HARRISON R A, TUMMALA S, GROOT J D. Neurologic toxicities of cancer immunotherapies: a review[J/OL]. Curr Neurol Neurosci Rep, 2020, 20(7): 27 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/32514633/. DOI: 10.1007/s11910-020-01038-2.
[8]
MARINI A, BERNARDINI A, GIGLI G L, et al. Neurologic adverse events of immune checkpoint inhibitors: A systematic review[J]. Neurology, 2021, 96(16): 754-766. DOI: 10.1212/WNL.0000000000011795.
[9]
ALBARRÁN V, CHAMORRO J, ROSERO D I, et al. Neurologic toxicity of immune checkpoint inhibitors: a review of literature[J/OL]. Front Pharmacol, 2022, 13: 774170 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/32514633/. DOI: 10.3389/fphar.2022.774170.
[10]
MARTINS F, SOFIYA L, SYKIOTIS G P, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance[J]. Nat Rev Clin Oncol, 2019, 16(9): 563-580. DOI: 10.1038/s41571-019-0218-0.
[11]
MÜLLER-JENSEN L, ZIEROLD S, VERSLUIS J M, et al. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study[J]. Eur J Cancer, 2022, 175: 224-235. DOI: 10.1016/j.ejca.2022.08.009.
[12]
NANNINI S, KOSHENKOVA L, BALOGLU S, et al. Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review[J]. J Neurooncol, 2022, 157(3): 533-550. DOI: 10.1007/s11060-022-03997-7.
[13]
DUONG S L, BARBIERO F J, NOWAK R J, et al. Neurotoxicities associated with immune checkpoint inhibitor therapy[J]. J Neurooncol, 2021, 152(2): 265-277. DOI: 10.1007/s11060-021-03695-w.
[14]
JOHNSON D B, MANOUCHEHRI A, HAUGH A M, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study[J/OL]. J Immunother Cancer, 2019, 7(1): 134 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/31118078/. DOI: 10.1186/s40425-019-0617-x.
[15]
MIKAMI T, LIAW B, ASADA M, et al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database[J]. J Neurooncol, 2021, 152(1): 135-144. DOI: 10.1007/s11060-020-03687-2.
[16]
SHI J Y, NIU J W, SHEN D C, et al. Clinical diagnosis and treatment recommendations for adverse reaction in the nervous system related to immunocheckpoint inhibitor[J]. Chin J Lung Cancer, 2019, 22(10): 633-638. DOI: 10.3779/j.issn.1009-3419.2019.10.05.
[17]
HAANEN J B A G, CARBONNEL F, ROBERT C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J/OL]. Ann Oncol, 2018, 29(Suppl 4): iv264-iv266 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/28881921/. DOI: 10.1093/annonc/mdy162.
[18]
HAUGH A M, PROBASCO J C, JOHNSON D B. Neurologic complications of immune checkpoint inhibitors[J]. Expert Opin Drug Saf, 2020, 19(4): 479-488. DOI: 10.1080/14740338.2020.1738382.
[19]
HECKER C, WELPONER T, HEROLD M, et al. Update on treatment strategies for vasculitis affecting the central nervous system[J]. Drug Discov Today, 2022, 27(4): 1142-1155. DOI: 10.1016/j.drudis.2021.11.020.
[20]
NEHME A, BOULANGER M, AOUBA A, et al. Diagnostic and therapeutic approach to adult central nervous system vasculitis[J]. Rev Neurol, 2022, 178(10): 1041-1054. DOI: 10.1016/j.neurol.2022.05.003.
[21]
HAJJ-ALI R A, CALABRESE L H. Diagnosis and classification of central nervous system vasculitis[J]. J Autoimmun, 2014, 48/49: 149-152. DOI: 10.1016/j.jaut.2014.01.007.
[22]
JUNEK M, PERERA K S, KICZEK M, et al. Current and future advances in practice: a practical approach to the diagnosis and management of primary central nervous system vasculitis[J/OL]. Rheumatol Adv Pract, 2023, 7(3): rkad080 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/38091383/. DOI: 10.1093/rap/rkad080.
[23]
MANSUETO G, LANZA G, FISICARO F, et al. Central and peripheral nervous system complications of vasculitis syndromes from pathology to bedside: part 1-central nervous system[J]. Curr Neurol Neurosci Rep, 2022, 22(1): 47-69. DOI: 10.1007/s11910-022-01172-z.
[24]
PATZIG M, FORBRIG R, KÜPPER C, et al. Diagnosis and follow-up evaluation of central nervous system vasculitis: an evaluation of vessel-wall MRI findings[J]. J Neurol, 2022, 269(2): 982-996. DOI: 10.1007/s00415-021-10683-7.
[25]
AGARWAL S, SEBASTIAN L J D, GAIKWAD S, et al. The role of susceptibility-weighted imaging & contrast-enhanced MRI in the diagnosis of primary CNS vasculitis: a large case series[J/OL]. Sci Rep, 2024, 14(1): 4718 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/38413676/. DOI: 10.1038/s41598-024-55222-2.
[26]
Neuroimmunology Branch of the National Society of Immunology; Neuroimmunology Group of Neurology Branch of Chinese Medical Association; Neuroimmunology Specialist Committee of the Neurology Branch of the Chinese Medical Association. China expert consensus on diagnosis and treatment of primary central nervous system vasculitis[J]. Chin J Neuroimmunol Neurol, 2017, 24(4): 229-239. DOI: 10.3969/j.issn.1006-2963.2017.04.001.
[27]
HAMADA N, MAEDA A, TAKASE-MINEGISHI K, et al. Incidence and distinct features of immune checkpoint inhibitor-related Myositis from idiopathic inflammatory Myositis: a single-center experience with systematic literature review and meta-analysis[J/OL]. Front Immunol, 2021, 12: 803410 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/34938300/. DOI: 10.3389/fimmu.2021.803410.
[28]
CAPPELLI L C, GUTIERREZ A K, BINGHAM C O, et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature[J]. Arthritis Care Res, 2017, 69(11): 1751-1763. DOI: .
[29]
KAO J C, LIAO B, MARKOVIC S N, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies[J]. JAMA Neurol, 2017, 74(10): 1216-1222. DOI: .
[30]
MOREIRA A, LOQUAI C, PFÖHLER C, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors[J]. Eur J Cancer, 2019, 106: 12-23. DOI: .
[31]
TOUAT M, TALMASOV D, RICARD D, et al. Neurological toxicities associated with immune-checkpoint inhibitors[J]. Curr Opin Neurol, 2017, 30(6): 659-668. DOI: 10.1097/WCO.0000000000000503.
[32]
JORDAN B, BENESOVA K, HASSEL J C, et al. How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors[J]. ESMO Open, 2021, 6(6): 100317. DOI: 10.1016/j.esmoop.2021.100317.
[33]
PSIMARAS D, VELASCO R, BIRZU C, et al. Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment[J]. J Peripher Nerv Syst, 2019, 24(Suppl 2): S74-S85. DOI: 10.1111/jns.12339.
[34]
GARIBALDI M, CALABRÒ F, MERLONGHI G, et al. Immune checkpoint inhibitors (ICIs)-related ocular myositis[J]. Neuromuscul Disord, 2020, 30(5): 420-423. DOI: 10.1016/j.nmd.2020.02.013.
[35]
ALBAYDA J, DEMONCEAU G, CARLIER P G. Muscle imaging in myositis: MRI, US, and PET[J/OL]. Best Pract Res Clin Rheumatol, 2022, 36(2): 101765 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/34938300/. DOI: 10.1016/j.berh.2022.101765.
[36]
PIPITONE N. Value of MRI in diagnostics and evaluation of myositis[J]. Curr Opin Rheumatol, 2016, 28(6): 625-630. DOI: 10.1097/BOR.0000000000000326.
[37]
MCCULLOUGH M B, DOMIRE Z J, REED A M, et al. Evaluation of muscles affected by myositis using magnetic resonance elastography[J]. Muscle Nerve, 2011, 43(4): 585-590. DOI: 10.1002/mus.21923.
[38]
WASSERMAN P L, WAY A, BAIG S, et al. MRI of myositis and other urgent muscle-related disorders[J]. Emerg Radiol, 2021, 28(2): 409-421. DOI: 10.1007/s10140-020-01866-2.
[39]
ALDRICH J, PUNDOLE X, TUMMALA S, et al. Inflammatory Myositis in cancer patients receiving immune checkpoint inhibitors[J]. Arthritis Rheumatol, 2021, 73(5): 866-874. DOI: 10.1002/art.41604.
[40]
NEBHAN C A, CORTELLINI A, MA W J, et al. Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study[J]. JAMA Oncol, 2021, 7(12): 1856-1861. DOI: 10.1001/jamaoncol.2021.4960.
[41]
SUIJKERBUIJK K P M, VAN EIJS M J M, VAN WIJK F, et al. Clinical and translational attributes of immune-related adverse events[J]. Nat Cancer, 2024, 5(4): 557-571. DOI: 10.1038/s43018-024-00730-3.
[42]
MALARTRE S, BACHASSON D, MERCY G, et al. MRI and muscle imaging for idiopathic inflammatory myopathies[J/OL]. Brain Pathol, 2021, 31(3): e12954 [2024-11-25]. https://pubmed.ncbi.nlm.nih.gov/34043260/. DOI: 10.1111/bpa.12954.

PREV
NEXT Consensus of Chinese experts on cardiovascular MRI in evaluating immune-related adverse cardiac events associated with immune checkpoint inhibitors for malignant tumors
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn